Clínic Barcelona. Hospital Universitari
<< More news

News

September 5, 2016

Development of microfluidic devices and microchips for the evaluation and monitoring of hemostasis

Investigators of the Departments of Hemotherapy and Hemostasis (CBD), in collaboration with other members of the "Atherothrombosis Research Unit" Cardiovascular Institute, Mount Sinai Hospital, New York and input from experts in Bioengineering and Biomaterials at the University Pompeu Fabra (UPC) will receive funding from ISCIII for a project submitted to a recent call from the Strategic Health Action of the Spanish Government (AES2016).
The project entitled: "“Microchip-based point of care devices for a global evaluation of hemostasis under flow conditions: application to the screening of bleeding, thrombosis and monitoring of antithrombotic therapies” is led by Dr. Gines Escolar of the Department of Hemotherapy and Hemostasis (CDB) and with an ultimate objective aimed at the development of small sized devices that can be used for diagnosis of thrombotic-hemorrhagic diseases, for evaluation of reactivity of prosthetic materials and to monitor antithrombotic treatments. An innovative aspect of this proposal is the integration of novel microsensors into miniaturized microfluidic devices connectable to hand-held technologies (cell phones or tablets), to provide a faster and precise evaluation of physiological hemostasis and effects of antithrombotic drugs.
This objective will be accomplished through the interactions of researchers who gather experience in hemorrhagic and thrombotic conditions and their assessment in traditional and advanced laboratory systems, combined with the experience in new materials and design capabilities of microfluidic devices provided by researchers specialized in bioengineering. The project is strategically supported by two commercial companies interested in the diagnosis of hemostasis disorders and the development and application of microfluidic systems to different experimental and clinical conditions. The active involvement implication of the CDB management engaging the interest of these companies has played a critical role in the success of the proposal.

 

Biomedical Diagnostic Center (CDB)

Villarroel, 170 · 08036 Barcelona
Tel: +34 93 227 54 64 · Fax: +34 93 227 98 75 · · www.hospitalclinic.org